Published in Antimicrob Agents Chemother on November 05, 2012
Selective photoinactivation of Candida albicans in the non-vertebrate host infection model Galleria mellonella. BMC Microbiol (2013) 0.83
Real-time evaluation of two light delivery systems for photodynamic disinfection of Candida albicans biofilm in curved root canals. Lasers Med Sci (2014) 0.78
Blue light treatment of Pseudomonas aeruginosa: Strong bactericidal activity, synergism with antibiotics and inactivation of virulence factors. Virulence (2016) 0.77
Growth Inhibition and Membrane Permeabilization of Candida lusitaniae Using Varied Pulse Shape Electroporation. Biomed Res Int (2015) 0.75
Virulence factors of fluconazole-susceptible and fluconazole-resistant Candida albicans after antimicrobial photodynamic therapy. Lasers Med Sci (2017) 0.75
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Virulence factors of Candida albicans. Trends Microbiol (2001) 5.01
Transcriptional response of Candida albicans upon internalization by macrophages. Eukaryot Cell (2004) 4.28
Simplified agar plate method for quantifying viable bacteria. Biotechniques (1997) 3.90
Serum tube identification of Candida albicans. J Clin Pathol (1962) 3.54
Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Mol Microbiol (2005) 3.00
Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol (2002) 2.94
Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis (2005) 2.42
Morphogenesis in Candida albicans. Annu Rev Microbiol (2007) 2.39
Complex cellular responses to reactive oxygen species. Trends Cell Biol (2005) 2.09
Fungal invasion of normally non-phagocytic host cells. PLoS Pathog (2006) 1.83
Candida albicans hyphal formation and the expression of the Efg1-regulated proteinases Sap4 to Sap6 are required for the invasion of parenchymal organs. Infect Immun (2002) 1.82
Photodynamic therapy for localized infections--state of the art. Photodiagnosis Photodyn Ther (2009) 1.73
Evolution of drug resistance in Candida albicans. Annu Rev Microbiol (2002) 1.67
Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother (2008) 1.62
Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity. FEMS Yeast Res (2006) 1.54
Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol (2011) 1.51
Photoinactivation of bacterial strains involved in periodontal diseases sensitized by porphycene-polylysine conjugates. Photochem Photobiol Sci (2002) 1.41
Interaction of pathogenic yeasts with phagocytes: survival, persistence and escape. Curr Opin Microbiol (2010) 1.39
Arginine-induced germ tube formation in Candida albicans is essential for escape from murine macrophage line RAW 264.7. Infect Immun (2009) 1.38
Stress-induced phenotypic switching in Candida albicans. Mol Biol Cell (2009) 1.37
Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans. Infect Immun (2007) 1.36
The effect of photodynamic action on two virulence factors of gram-negative bacteria. Photochem Photobiol (2000) 1.30
Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B (2000) 1.27
Hydrogen peroxide causes RAD9-dependent cell cycle arrest in G2 in Saccharomyces cerevisiae whereas menadione causes G1 arrest independent of RAD9 function. J Biol Chem (1998) 1.19
Animal models in the analysis of Candida host-pathogen interactions. Curr Opin Microbiol (2004) 1.09
Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Front Microbiol (2012) 1.07
Survival of starving yeast is correlated with oxidative stress response and nonrespiratory mitochondrial function. Proc Natl Acad Sci U S A (2011) 1.05
Photodynamic antimicrobial chemotherapy (PACT) with methylene blue increases membrane permeability in Candida albicans. Lasers Med Sci (2007) 1.03
Study of germ tube formation by Candida albicans after photodynamic antimicrobial chemotherapy (PACT). J Photochem Photobiol B (2007) 0.98
The importance of strain variation in virulence of Candida dubliniensis and Candida albicans: results of a blinded histopathological study of invasive candidiasis. Clin Microbiol Infect (2009) 0.98
Mechanisms of immune evasion in fungal pathogens. Curr Opin Microbiol (2011) 0.97
Sensitivity of Candida albicans germ tubes and biofilms to photofrin-mediated phototoxicity. Antimicrob Agents Chemother (2005) 0.96
Influence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of Candida albicans. J Antimicrob Chemother (2011) 0.95
In vitro photodynamic inactivation of Candida spp. growth and adhesion to buccal epithelial cells. J Photochem Photobiol B (2008) 0.94
Apoptosis, autophagy and cell cycle arrest following photodamage to mitochondrial interior. Apoptosis (2009) 0.93
Effects of singlet oxygen on membrane sterols in the yeast Saccharomyces cerevisiae. Eur J Biochem (2000) 0.89
Diallyl disulphide depletes glutathione in Candida albicans: oxidative stress-mediated cell death studied by two-photon microscopy. Yeast (2007) 0.89
Killing of methicillin-resistant Staphylococcus aureus in vitro using aluminium disulphonated phthalocyanine, a light-activated antimicrobial agent. J Antimicrob Chemother (1997) 0.88
Inactivation of staphylococcal virulence factors using a light-activated antimicrobial agent. BMC Microbiol (2009) 0.88
Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults. Int J Antimicrob Agents (2006) 0.88
Intracellular damage in yeast cells caused by photodynamic treatment with toluidine blue. Photochem Photobiol (1995) 0.88
Phenotypic screening, transcriptional profiling, and comparative genomic analysis of an invasive and non-invasive strain of Candida albicans. BMC Microbiol (2008) 0.85
Miconazole induces fungistasis and increases killing of Candida albicans subjected to photodynamic therapy. Photochem Photobiol (2011) 0.85
Effect of sub-lethal challenge with Photodynamic Antimicrobial Chemotherapy (PACT) on the antibiotic susceptibility of clinical bacterial isolates. J Photochem Photobiol B (2010) 0.85
Pharmacotherapy of yeast infections. Expert Opin Pharmacother (2008) 0.83
Inhibition of transport systems in yeast by photodynamic treatment with toluidine blue. Biochim Biophys Acta (1993) 0.82
Combined inactivation of the Candida albicans GPR1 and TPS2 genes results in avirulence in a mouse model for systemic infection. Infect Immun (2008) 0.82
Electrochemical DNA biosensor for the detection of short DNA species of Chronic Myelogenous Leukemia by using methylene blue. Talanta (2006) 0.79
Development of oxidative stress tolerance resulted in reduced ability to undergo morphologic transitions and decreased pathogenicity in a t-butylhydroperoxide-tolerant mutant of Candida albicans. FEMS Yeast Res (2007) 0.79
Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 6.08
Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer (2006) 3.93
Google trends: a web-based tool for real-time surveillance of disease outbreaks. Clin Infect Dis (2009) 3.90
A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature (2008) 3.00
Biphasic dose response in low level light therapy. Dose Response (2009) 2.78
Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis (2009) 2.72
Retracted Human immunodeficiency virus infection and the thyroid. Thyroid (2002) 2.68
The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng (2011) 2.37
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A (2009) 2.35
Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J Exp Med (2004) 2.12
Medically important bacterial-fungal interactions. Nat Rev Microbiol (2010) 2.10
Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog (2007) 2.05
Virulence effect of Enterococcus faecalis protease genes and the quorum-sensing locus fsr in Caenorhabditis elegans and mice. Infect Immun (2002) 1.96
Effect of cell-photosensitizer binding and cell density on microbial photoinactivation. Antimicrob Agents Chemother (2005) 1.89
Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence (2010) 1.88
Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother (2009) 1.86
Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J Exp Med (2009) 1.84
Role of low-level laser therapy in neurorehabilitation. PM R (2010) 1.79
Low-level laser therapy activates NF-kB via generation of reactive oxygen species in mouse embryonic fibroblasts. PLoS One (2011) 1.76
Photodynamic therapy for localized infections--state of the art. Photodiagnosis Photodyn Ther (2009) 1.73
Antibacterial bioagents based on principles of bacteriophage biology: an overview. Clin Infect Dis (2013) 1.70
Biphasic dose response in low level light therapy - an update. Dose Response (2011) 1.69
Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus. ACS Chem Biol (2010) 1.64
The prevalence and significance of methicillin-resistant Staphylococcus aureus colonization at admission in the general ICU Setting: a meta-analysis of published studies. Crit Care Med (2014) 1.61
Protease-stable polycationic photosensitizer conjugates between polyethyleneimine and chlorin(e6) for broad-spectrum antimicrobial photoinactivation. Antimicrob Agents Chemother (2006) 1.58
Targeted photodynamic therapy of established soft-tissue infections in mice. Photochem Photobiol Sci (2004) 1.57
Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog (2007) 1.55
Disruption of the Aspergillus fumigatus gene encoding nucleolar protein CgrA impairs thermotolerant growth and reduces virulence. Infect Immun (2004) 1.52
Using non-mammalian hosts to study fungal virulence and host defense. Curr Opin Microbiol (2006) 1.52
Use of chitosan bandage to prevent fatal infections developing from highly contaminated wounds in mice. Biomaterials (2006) 1.51
Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. Proc Natl Acad Sci U S A (2008) 1.51
Photodynamic therapy for Acinetobacter baumannii burn infections in mice. Antimicrob Agents Chemother (2009) 1.50
Monitoring photodynamic therapy of localized infections by bioluminescence imaging of genetically engineered bacteria. J Photochem Photobiol B (2005) 1.50
Antimicrobial effects of photodynamic therapy on patients with necrotic pulps and periapical lesion. J Endod (2007) 1.46
Light-emitting diode therapy (LEDT) before matches prevents increase in creatine kinase with a light dose response in volleyball players. Lasers Med Sci (2015) 1.46
Cell death pathways in photodynamic therapy of cancer. Cancers (Basel) (2011) 1.45
Challenge of Drosophila melanogaster with Cryptococcus neoformans and role of the innate immune response. Eukaryot Cell (2004) 1.45
Photodynamic therapy for methicillin-resistant Staphylococcus aureus infection in a mouse skin abrasion model. Lasers Surg Med (2010) 1.45
Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain. Microbes Infect (2007) 1.44
Can surgical site infections be treated by photodynamic therapy? Photodiagnosis Photodyn Ther (2010) 1.43
New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis (2006) 1.42
Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond? Drug Resist Updat (2012) 1.42
Photodynamic therapy for infections: clinical applications. Lasers Surg Med (2011) 1.42
Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. Infect Immun (2006) 1.41
Improved cognitive function after transcranial, light-emitting diode treatments in chronic, traumatic brain injury: two case reports. Photomed Laser Surg (2010) 1.38
Loss of cell wall alpha(1-3) glucan affects Cryptococcus neoformans from ultrastructure to virulence. Mol Microbiol (2007) 1.38
Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism. Free Radic Biol Med (2007) 1.37
Low-level laser therapy for zymosan-induced arthritis in rats: Importance of illumination time. Lasers Surg Med (2007) 1.36
Low-level light stimulates excisional wound healing in mice. Lasers Surg Med (2007) 1.36
Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. Behav Brain Funct (2009) 1.35
Candida infection and colonization among trauma patients. Virulence (2010) 1.34
Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg (2013) 1.34
Candida albicans hyphal formation and virulence assessed using a Caenorhabditis elegans infection model. Eukaryot Cell (2009) 1.33
Antimicrobial photodynamic therapy combined with conventional endodontic treatment to eliminate root canal biofilm infection. Lasers Surg Med (2007) 1.33
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
Efflux in fungi: la pièce de résistance. PLoS Pathog (2009) 1.33
Photodynamic therapy with fullerenes. Photochem Photobiol Sci (2007) 1.32
Effects of growth phase and extracellular slime on photodynamic inactivation of gram-positive pathogenic bacteria. Antimicrob Agents Chemother (2004) 1.31
Photodynamic therapy for Staphylococcus aureus infected burn wounds in mice. Photochem Photobiol Sci (2005) 1.29
Management of mouth opening in patients with temporomandibular disorders through low-level laser therapy and transcutaneous electrical neural stimulation. Photomed Laser Surg (2006) 1.28
Our paths might cross: the role of the fungal cell wall integrity pathway in stress response and cross talk with other stress response pathways. Eukaryot Cell (2009) 1.28
Cationic fullerenes are effective and selective antimicrobial photosensitizers. Chem Biol (2005) 1.28
Candida infection and colonization among non-trauma emergency surgery patients. Virulence (2010) 1.27
Candida albicans infection of Caenorhabditis elegans induces antifungal immune defenses. PLoS Pathog (2011) 1.24
Role of filamentation in Galleria mellonella killing by Candida albicans. Microbes Infect (2010) 1.23
Efficiency of NaOCl and laser-assisted photosensitization on the reduction of Enterococcus faecalis in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2006) 1.23
Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci U S A (2008) 1.23
Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects. Expert Rev Anti Infect Ther (2011) 1.23
Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS One (2009) 1.22
Phenothiazinium antimicrobial photosensitizers are substrates of bacterial multidrug resistance pumps. Antimicrob Agents Chemother (2006) 1.22
Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opin Pharmacother (2008) 1.22
Effect of pulsing in low-level light therapy. Lasers Surg Med (2010) 1.21
Antimicrobial and efflux pump inhibitory activity of caffeoylquinic acids from Artemisia absinthium against gram-positive pathogenic bacteria. PLoS One (2011) 1.21
The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii. Infect Immun (2009) 1.21
Contribution of gelatinase, serine protease, and fsr to the pathogenesis of Enterococcus faecalis endophthalmitis. Infect Immun (2004) 1.21
Shock wave-mediated molecular delivery into cells. Biochim Biophys Acta (2002) 1.19
Innate recognition of cell wall β-glucans drives invariant natural killer T cell responses against fungi. Cell Host Microbe (2011) 1.18
Eca1, a sarcoplasmic/endoplasmic reticulum Ca2+-ATPase, is involved in stress tolerance and virulence in Cryptococcus neoformans. Infect Immun (2007) 1.17
Natalizumab and HSV meningitis. J Neurovirol (2011) 1.16
Helicobacter pylori in patients can be killed by visible light. Lasers Surg Med (2005) 1.15
Comparison of therapeutic effects between pulsed and continuous wave 810-nm wavelength laser irradiation for traumatic brain injury in mice. PLoS One (2011) 1.15
Low-level laser therapy for closed-head traumatic brain injury in mice: effect of different wavelengths. Lasers Surg Med (2012) 1.15
Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response. Cancer Res (2009) 1.14
Cryptococcus neoformans gene involved in mammalian pathogenesis identified by a Caenorhabditis elegans progeny-based approach. Infect Immun (2005) 1.13
Antimicrobial strategies centered around reactive oxygen species--bactericidal antibiotics, photodynamic therapy, and beyond. FEMS Microbiol Rev (2013) 1.13
Photodynamic inactivation of Acinetobacter baumannii using phenothiazinium dyes: in vitro and in vivo studies. Lasers Surg Med (2010) 1.12